Emerald Mutual Fund Advisers Trust Has $13.65 Million Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Emerald Mutual Fund Advisers Trust cut its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 24.4% during the 4th quarter, Holdings Channel reports. The institutional investor owned 324,437 shares of the biopharmaceutical company’s stock after selling 104,865 shares during the quarter. Emerald Mutual Fund Advisers Trust’s holdings in Ultragenyx Pharmaceutical were worth $13,649,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in RARE. Smartleaf Asset Management LLC raised its stake in shares of Ultragenyx Pharmaceutical by 259.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 493 shares during the last quarter. Aster Capital Management DIFC Ltd bought a new position in Ultragenyx Pharmaceutical during the 4th quarter worth $35,000. Human Investing LLC acquired a new position in Ultragenyx Pharmaceutical during the 4th quarter worth about $42,000. Van ECK Associates Corp grew its position in shares of Ultragenyx Pharmaceutical by 18.4% in the 4th quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 273 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of Ultragenyx Pharmaceutical in the third quarter valued at about $83,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Ultragenyx Pharmaceutical Trading Down 0.3 %

Shares of RARE stock opened at $37.98 on Tuesday. The firm has a market capitalization of $3.57 billion, a PE ratio of -5.99 and a beta of 0.61. The firm has a fifty day simple moving average of $37.79 and a two-hundred day simple moving average of $43.54. Ultragenyx Pharmaceutical Inc. has a 12 month low of $29.59 and a 12 month high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.32) by ($0.07). The company had revenue of $164.88 million for the quarter, compared to analyst estimates of $163.23 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. On average, equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Analysts Set New Price Targets

RARE has been the topic of a number of recent analyst reports. Wedbush reaffirmed a “neutral” rating and issued a $48.00 price objective (up from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. Piper Sandler reduced their price objective on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an “overweight” rating on the stock in a research note on Monday, March 17th. Canaccord Genuity Group lifted their target price on shares of Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a “buy” rating in a research note on Tuesday, February 18th. HC Wainwright reaffirmed a “buy” rating and set a $95.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. Finally, JPMorgan Chase & Co. lifted their price objective on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an “overweight” rating in a research report on Thursday, March 27th. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $92.79.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 2,990 shares of the company’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $42.88, for a total value of $128,211.20. Following the completion of the sale, the executive vice president now directly owns 54,991 shares of the company’s stock, valued at approximately $2,358,014.08. This represents a 5.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Emil D. Kakkis sold 25,000 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $42.48, for a total transaction of $1,062,000.00. Following the transaction, the chief executive officer now directly owns 2,158,985 shares in the company, valued at approximately $91,713,682.80. This represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 124,643 shares of company stock worth $5,256,268. 5.50% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.